Welcome to our dedicated page for Faeth Therapeutics SEC filings (Ticker: FTH), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Faeth Therapeutics's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Faeth Therapeutics's regulatory disclosures and financial reporting.
Faeth Therapeutics, Inc. (FTH) reports that its Board of Directors increased in size from five to six members and appointed co‑founder and cancer biologist Karen Vousden, Ph.D. as a Class II director, effective September 11, 2026. Her term runs until the 2029 annual meeting of stockholders, and she was also named to the Board’s Compensation Committee. In connection with her appointment, Dr. Vousden will receive standard non‑employee director cash compensation and an initial equity award under the 2026 Equity Incentive Plan consisting of an option to purchase 25,000 shares of common stock at the closing market price on the grant date, vesting in equal monthly installments over three years and fully vesting upon a Change in Control, subject to continued service.
Faeth Therapeutics, Inc. (FTH) reported that director Karen H. Vousden received a stock option grant for 25,000 shares of common stock on September 11, 2026. The option has an exercise price of $37.44 per share, expires on September 10, 2036, and vests in 36 equal monthly installments through September 11, 2029, contingent on her continued service. No transactions were reported under a Rule 10b5-1 trading plan.
Faeth Therapeutics, Inc. (FTH) reports that director Karen H. Vousden has filed an initial statement of beneficial ownership on Form 3. The filing shows she holds 42,631 shares of the company's Common Stock with direct ownership, and it does not report any recent purchases or sales.
Faeth Therapeutics, Inc., formerly Sensei Biotherapeutics, Inc., reports that Caligan Partners LP and David Johnson have amended their ownership disclosure. They now report beneficial ownership of 629,467 shares of common stock, representing 2.4% of the class, based on 25,840,425 shares outstanding as of July 30, 2026. The shares are held with shared voting and dispositive power through funds and accounts managed by Caligan.
The company changed its corporate name to Faeth Therapeutics, Inc. on June 15, 2026, in connection with its acquisition of Faeth Holdings Therapeutics, Inc. and a concurrent private placement of Series B Non-Voting Convertible Preferred Stock, completed in February 2026. Following stockholder approval on June 10, 2026, these preferred shares automatically converted into common stock on June 15, 2026, and the common stock began trading on the Nasdaq Capital Market under the symbol FTH on June 16, 2026. The amendment states that the reporting persons have ceased to be beneficial owners of more than five percent of the class.
Faeth Therapeutics, Inc. received an amended Schedule 13G/A from Trails Edge Capital Partners, LP, Trails Edge Biotechnology Master Fund, LP, and Ortav Yehudai reporting their ownership of Faeth common stock. As of June 30, 2026, the filers may be deemed to beneficially own 515,335 shares of common stock, representing 2.0% of the company’s outstanding shares. All reported shares are held directly by Trails Edge Biotechnology Master Fund, with Trails Edge Capital as investment manager and Mr. Yehudai exercising voting and investment discretion. The ownership percentages are based on 25,778,754 Faeth common shares outstanding as of June 15, 2026. The filing also notes that the filers hold 5 percent or less of this class of securities.
Khosla Ventures-affiliated entities report a significant passive stake in Faeth Therapeutics, Inc. The group, including Khosla Ventures VI, LP, Khosla Ventures Seed D, LP, Khosla Ventures Associates VI, LLC, Khosla Ventures Seed Associates D, LLC, VK Services, LLC, and Vinod Khosla, reports aggregate beneficial ownership of 2,632,232 shares of Faeth Therapeutics common stock, representing 10.2% of the class.
The holdings are primarily through Khosla Ventures VI, LP with 1,643,349 shares (6.4%) and Khosla Ventures Seed D, LP with 988,883 shares (3.8%). All report shared voting and dispositive power over their respective shares and no sole voting or dispositive power. Ownership percentages are calculated based on 25,840,425 shares outstanding as of July 30, 2026. Each reporting person disclaims beneficial ownership beyond its pecuniary interest.
Faeth Therapeutics, Inc. received an amended ownership report from StemPoint Capital LP, StemPoint Capital Management GP LLC, and Michelle Ross. These reporting persons now state they beneficially own 0 shares of Faeth Therapeutics common stock, representing 0.0% of the class.
The percentage is calculated using 25,778,754 shares of common stock reported as issued and outstanding as of June 15, 2026. The amendment confirms they have no sole or shared voting or dispositive power over any shares and that they hold 5 percent or less of the class under Schedule 13G rules.
Cambrian Biopharma, Inc., as a holder of Faeth Therapeutics, Inc. common stock, has filed to sell up to 130,142 shares of Faeth Therapeutics common stock through Fidelity Brokerage Services LLC on NASDAQ, with a stated value of $3,642,675.00, beginning on or after July 22, 2026.
The filing also notes that during the past three months, Cambrian Biopharma sold 25,000 shares of Faeth Therapeutics common stock for $500,548.39 on June 1, 2026. The securities being sold were originally acquired in a private placement dated January 10, 2020 for cash.
Faeth Therapeutics, Inc. reported a net loss of $186.2 million for the six months ended June 30, 2026, largely driven by a $133.0 million acquired in-process R&D charge recognized in connection with its February 2026 acquisition of Faeth Therapeutics and related programs.
Excluding that nonrecurring charge, operating costs expanded as research and development expenses rose to $27.1 million and general and administrative expenses to $28.9 million, reflecting integration of the acquired business, higher personnel costs, and stock-based compensation. Cash, cash equivalents and marketable securities totaled $186.4 million as of June 30, 2026, following a $200.0 million Series B preferred stock private placement and subsequent conversion of most preferred shares into common stock.
Post-transaction, legacy Sensei stockholders held about 4.9% of the common equity on a fully diluted basis, former Faeth holders 40.6%, and new private placement investors 54.5%. Management states that the strengthened balance sheet is expected to fund operations through key clinical milestones for lead multi-node PI3K/AKT/mTOR inhibitor PIKTOR in endometrial and HR+/HER2- breast cancer.
Faeth Therapeutics, Inc. reported financial results for the quarter ended June 30, 2026 and provided clinical and corporate updates. The company highlighted its combination with Sensei Biotherapeutics and a concurrent $200 million PIPE financing, which it says provides capital to advance its multi-node inhibitor PIKTOR across multiple cancers.
For the quarter, total operating expenses were $18,385 (in thousands), up from $5,206 (in thousands) a year earlier, driven by research and development of $9,180 (in thousands) and general and administrative expenses of $9,205 (in thousands). Net loss was $16,007 (in thousands), compared with $4,936 (in thousands), or $2.84 net loss per share versus $3.91. Cash and cash equivalents were $26,903 (in thousands) and marketable securities were $159,538 (in thousands) as of June 30, 2026.
Operationally, Faeth reported that topline results from its Phase 2 PIK-201 trial in advanced endometrial cancer are on track for year-end 2026, and that the first patient was dosed in its Phase 1b/2 PIK-101 trial in HR+ breast cancer in April 2026, with initial data anticipated in 2027.